【摘要】：目的:系統(tǒng)評(píng)價(jià)N-乙酰半胱氨酸(NAC)治療特發(fā)性肺纖維化(IPF)的療效,為臨床提供循證參考。方法:計(jì)算機(jī)檢索Central數(shù)據(jù)庫(kù)、Pub Med、EMBase、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)、相關(guān)期刊論文、萬(wàn)方數(shù)據(jù)庫(kù)和中文科技期刊數(shù)據(jù)庫(kù),收集NAC(不限單藥或聯(lián)用)對(duì)比安慰劑/空白對(duì)照治療IPF的隨機(jī)對(duì)照試驗(yàn)(RCT)及半隨機(jī)對(duì)照試驗(yàn)(q RCT),提取資料并采用Cochrane協(xié)作網(wǎng)提供的偏倚風(fēng)險(xiǎn)評(píng)價(jià)工具(2014年版)評(píng)價(jià)質(zhì)量后,采用Rev Man 5.3統(tǒng)計(jì)軟件進(jìn)行Meta分析。結(jié)果:共納入10項(xiàng)研究(2項(xiàng)RCT,8項(xiàng)q RCT),合計(jì)742例患者。Meta分析結(jié)果顯示,與安慰劑/空白對(duì)照相比,使用NAC無(wú)法降低IPF患者的死亡率[OR=1.14,95%CI(0.50,2.62),P=0.76],但可以顯著提高IPF患者主癥狀緩解率[OR=3.17,95%CI(1.98,5.07),P0.001],改善患者呼吸困難評(píng)分[SMD=-2.54,95%CI(-5.02,-0.06),P=0.04]。結(jié)論:NAC治療IPF不能降低患者的死亡率,但可以緩解患者的主癥狀,改善呼吸困難。
[Abstract]:Objective: to systematically evaluate the efficacy of N-acetylcystine (NAC) in the treatment of (IPF) with Idiopathic pulmonary fibrosis and to provide evidence-based reference for clinic. Methods: Central database, Pub Med,EMBase, Chinese biomedical literature database, Chinese periodical full-text database, Wanfang database and Chinese sci-tech periodical database were searched by computer. Collection of NAC (unlimited single drug or combination) versus placebo / blank control treatment of IPF randomized controlled trial (RCT) and semi-randomized controlled trial (q RCT), After extracting the data and evaluating the quality by using the bias risk assessment tool provided by Cochrane collaboration network (2014 edition), the Meta analysis was carried out by using Rev Man 5.3 statistical software. Results: a total of 10 studies (2 RCT,8 items q RCT), total 742 patients) were included. Meta-analysis showed that NAC could not reduce mortality in patients with IPF compared with placebo / blank control [OR=1.14,95%CI (0.50,2.62). P 鈮，

本文編號(hào)：2484622